Insights

Innovative Diagnostic Technology Abogen has developed a pioneering saliva-based technology for cell research and diagnostics, providing an alternative to traditional blood samples. This innovation opens opportunities for partnerships with healthcare providers and diagnostic labs seeking more patient-friendly and efficient testing solutions.

Strong Funding Backing With a successful $700 million Series C funding round, Abogen demonstrates significant financial strength and investor confidence, enabling expansion into new markets and development of advanced biotechnological products such as mRNA vaccines and diagnostic tools.

Focus on mRNA Vaccines The company's recent initiatives include developing mRNA vaccines for Covid-19, dengue, and other infectious diseases, presenting sales opportunities with pharmaceutical companies and healthcare organizations seeking innovative vaccine solutions with potential global reach.

Strategic Collaborations Abogen has entered multiple partnerships with international organizations like CanSino, Walvax, and Abogen itself, aiming to develop inhalable vaccines and viral-vector platforms, which could facilitate co-marketing and licensing agreements targeting emerging infectious disease markets.

Growing Market Relevance Operating in the competitive biotech sector alongside major players, Abogen's focus on saliva-based diagnostics and mRNA vaccine development positions it well to capitalize on current market trends favoring minimally invasive testing and rapid vaccine deployment, creating numerous sales opportunities for innovative healthcare solutions.

Similar companies to Abogen, Inc.

Abogen, Inc. Tech Stack

Abogen, Inc. uses 8 technology products and services including Google Workspace, Font Awesome, React, and more. Explore Abogen, Inc.'s tech stack below.

Google Workspace
Email
Font Awesome
Font Scripts
React
Javascript Frameworks
Chart.js
Javascript Graphics
jQuery UI
Javascript Libraries
Amazon ALB
Load Balancers
PHP
Programming Languages
GoDaddy
Web Hosting

Media & News

Abogen, Inc.'s Email Address Formats

Abogen, Inc. uses at least 1 format(s):

Abogen, Inc. Email Formats	Example	Percentage
FLast@abogen.com	JDoe@abogen.com	44%
F.Last@abogen.com	J.Doe@abogen.com	6%
FLast@abogen.com	JDoe@abogen.com	44%
F.Last@abogen.com	J.Doe@abogen.com	6%

Frequently Asked Questions

Where is Abogen, Inc.'s headquarters located?

Abogen, Inc.'s main headquarters is located at 474 Congress Street Portland, Maine 04101 United States. The company has employees across 2 continents, including North AmericaAsia.

What is Abogen, Inc.'s phone number?

You can contact Abogen, Inc.'s main corporate office by phone at

+1-207-939-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Abogen, Inc.'s official website and social media links?

Abogen, Inc.'s official website is abogen.com and has social profiles on LinkedIn.

What is Abogen, Inc.'s SIC code NAICS code?

Abogen, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Abogen, Inc. have currently?

As of February 2026, Abogen, Inc. has approximately 3 employees across 2 continents, including North AmericaAsia. Key team members include Chief Innovation Officer: M. J.Chief Business Officer- Acting: M. S.President And Co-Founder: Y. B.. Explore Abogen, Inc.'s employee directory with LeadIQ.

What industry does Abogen, Inc. belong to?

Abogen, Inc. operates in the Biotechnology Research industry.

What technology does Abogen, Inc. use?

Abogen, Inc.'s tech stack includes Google WorkspaceFont AwesomeReactChart.jsjQuery UIAmazon ALBPHPGoDaddy.

What is Abogen, Inc.'s email format?

Abogen, Inc.'s email format typically follows the pattern of FLast@abogen.com. Find more Abogen, Inc. email formats with LeadIQ.

How much funding has Abogen, Inc. raised to date?

As of February 2026, Abogen, Inc. has raised $700M in funding. .

When was Abogen, Inc. founded?

Abogen, Inc. was founded in 2012.

Abogen, Inc.

Q: What is Abogen, Inc.'s official website and social media links?

Abogen, Inc.'s official website is abogen.com. Abogen, Inc. has social profiles on LinkedIn.

Q: How many employees does Abogen, Inc. have currently?

Abogen, Inc. has approximately 3 employees.

Q: What technology does Abogen, Inc. use?

Abogen, Inc.'s tech stack includes jQuery UI, jQuery, PHP, Modernizr, GoDaddy.

Biotechnology ResearchMaine, United States2-10 Employees

At AboGen, we believe that drawing large volumes of blood using invasive needles for research and diagnostic purposes does not fit with the 21st century.
Founded in 2012, AboGen Inc. is the world's first company to show, through various independent 3rd party validators, that its technology can allow for the use of saliva, instead of blood, for various cell based research and diagnostic applications, including serological and genetic. 
We do not plan on replacing blood completely but we do plan on elevating saliva, as an alternative to blood for various cell based diagnostic applications, ABOve and beyond GENetic applications.

Company Overview

Headquarters: 474 Congress Street Portland, Maine 04101 United States
Phone number: +1-207-939-****
Website: abogen.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2012
Employees: 2-10